David Grayzel is a partner at Atlas Venture where he focuses on incubating and launching novel, therapeutic drug discovery companies. Since joining Atlas in 2010, David has co-founded and served as chief executive officer of numerous companies including Arteaus Therapeutics (acquired by Eli Lilly), Annovation Biopharma (acquired by The Medicines Company), and was a founding board member of both Delinia (acquired by Celgene), and Cadent Therapeutics (acquired by Novartis). David is a co-founder and board member of Q32 Bio (NASDAQ: QTTB) and Vima Therapeutics, and also sits on the boards of Affinia Therapeutics, Comanche Biopharma, and TRIANA Biomedicines. He was previously a board director of Surface Oncology (acquired by Coherus), Xilio Therapeutics (NASDAQ: XLO), and a board observer at Day One Biopharmaceuticals (NASDAQ: DAWN).

In addition, David serves or has served as an advisor to several organizations including Memorial Sloan Kettering Cancer Center’s (MSKCC) Technology Development Fund, the Tri-Institutional Therapeutics Discovery Institute, and the American Heart Association’s One Brave Idea. He earned his B.A. with honors from Stanford University, an M.D. from Harvard Medical School, and completed his internship and residency training in internal medicine at the Massachusetts General Hospital.